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INTRODUCTION                                                                  
Congenital heart disease (CHD) is the predominant form of heart 
disease among pregnant women in developed countries.(1) Since CHD 
is diagnosed and managed earlier, an increasing number of women with 
CHD are reaching childbearing age and are considering pregnancy. 
CHD does not preclude a successful pregnancy but increases the risk 
to both mother and child, requiring special management. In patients 
with repaired complex CHD, some uncertainties still remain about the 
ability to conceive, the effects of pregnancy on maternal heart disease, 
and the effects of heart disease on the fetus. The management of 
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patients with complex CHD during pregnancy requires a collaborative 
approach between obstetrician, cardiologist and neonatologist to 
provide the optimal environment for a safe and healthy pregnancy and 
childbirth. Inheritance of CHD should be discussed and parents should 
receive appropriate counseling. Fetal or postnatal echocardiography 
should be performed if indicated. 
PREVALENCE OF CHD                                                     
Cardiac malformations constitute a major percentage of signifi cant 
birth defects, with an estimated prevalence of 0.8%.(2,3) The true 
prevalence may be higher, as bicuspid aortic valve is usually excluded 
from this estimate and occurs in 10 to 20 per 1000 in the general 
population.(4) Including atrial septal aneurysm and persistent left 
superior vena cava, each occurring in 5 to 10 per 1000 live births, as 
well as ventricular septal defects occurring in up to 5% of newborns, an 
incidence of 5% CHD in live births is an underestimate.(5-9) Dramatic 
advances in medical care of children with CHD over the past decade 
have made survival into adulthood a reality, thus increasing the 
population of adults with CHD by 5% per year.(10) Thus the number of 
adults with CHD has surpassed the number of children with CHD in 
developed countries.(11)
GENETIC BASIS OF CHD                                                
Patients should be counseled about the increased risk of CHD in the 
fetus. The offspring of women with CHD have a 5% to 6% incidence of 
CHD. In the largest study on pregnancy in CHD, recurrence of CHD 
varied between 0.6% in transposition of the great arteries (TGA) to 8% 
in atrioventricular septal defect.(12) 
The CHD in the offspring is not always the same as in the mother with 
CHD. In syndromes the incidence of recurrence with each pregnancy 
may be up to 50% (e.g. autosomal dominant disorders such as familial 
atrial septal defect or bicuspid aortic valve). Bicuspid aortic valve is 
inherited in most patients and occurs in 37-89% of family members and 
family screening is recommended.(13,14) In relatives of patients with left 
ventricular outfl ow tract lesions, discordant CHD such as abnormalities 
of the left ventricle and mitral valve frequently occur.(15) In nonsyndromic 
CHD due to a multifactorial mechanism of inheritance, the cardiac 
defects in relatives may be different than in the index patient. (16,17)
It is important to identify the underlying genetic pattern as there may 
be involvement of organ systems other than the heart. In addition, it 
provides prognostic information for outcome, and there may be other 
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family members for whom genetic testing is appropriate.(11) Some of 
the genetic defects known in CHD are shown in Table I.
There are various genetic tests that can assist the physician in diagnosing 
genetic alterations in a patient with CHD including cytogenetic 
techniques, fl uorescence in situ hybridization (FISH), and DNA mutation 
analysis.(11) Chromosome analysis may reveal chromosomal aberration 
in 8-13% of neonates with CHD.(18) Common genetic defects include: 
22q11 deletion, microdeletion 7q11.23, or deletions 20p12. Genetic 
testing may determine a mechanism of disease and provides an 
important basis for genetic counseling. Preimplantation genetic testing 
is another available option for patients with CHD, undergoing certain 
methods of assisted reproduction.
PHYSIOLOGIC HEMODYNAMIC CHANGES DURING 
PREGNANCY, DELIVERY AND POSTPARTUM
Due to hormonal changes that relax smooth muscle followed by 
formation of the placenta and fetal circulation, the blood volume 
increases during pregnancy from the fi fth week into the third trimester. 
There is an up to 50% increase in circulating blood volume.(19) During 
pregnancy, there is a reduction in systemic and pulmonary vascular 
resistance and a slight decrease in blood pressure. The heart rate 
increases about 10-20 beats per minute. These hemodynamic changes 
result in a steady increase in cardiac output during pregnancy until the 
32nd week, at which time cardiac output and oxygen consumption 
plateau at 30-50% above the prepregnancy level. 
At the time of delivery, cardiac output increases as much as 80% above 
the prepregnancy level and may be as great as 9 L/min. Approximately 
500 mL of blood is lost at the time of vaginal delivery, and approximately 
1 000 mL during a normal caesarean delivery. (20, 21)
Normally, the hemodynamic changes that occur during pregnancy are 
well tolerated by the mother. However, CHD may be initially identifi ed 
during pregnancy because of increased cardiac output or because 
minor preexisting symptoms may be exacerbated.
TIME AND ROUTE OF DELIVERY                                   
The time and route of delivery and optimal anesthesia and analgesia 
should be planned before the onset of spontaneous labor to facilitate 
the delivery and to intervene as appropriate. With few exceptions, 
vaginal delivery is preferred for women with CHD. For attempted 
vaginal delivery, epidural anaesthesia to obtund the sympathetic 
response is a key aspect of management. Instrumentation (forceps or 
vacuum extraction) should only be used if necessary. Caesarean delivery 
is indicated for obstetric reasons and for patients with preterm labor 
while anticoagulated with warfarin. The fetus remains anticoagulated 
despite reversing the warfarin effect in the mother, and therefore is at 
risk of fetal intracranial hemorrhage. Caesarean delivery should also be 
considered for patients with fi xed cardiac obstructive lesions, patients 
with unstable aortic lesions at risk of dissection and for patients with 
deteriorating functional status. Most would also suggest that patients 
with pulmonary hypertension be considered for cesarean delivery. 
Most of these patients should be managed in a tertiary care center.
PRINCIPLES OF MANAGEMENT OF PREGNANCY IN 
WOMEN WITH CHD
Women with CHD should undergo a detailed assessment of any 
cardiac abnormality to determine the maternal and fetal risks of 
pregnancy antepartum. The safety of the mother is the highest priority. 
Fetal growth and development are monitored with ultrasonography. 
Fetal cardiac ultrasonography is recommended in women with CHD 
between the 18th to 20th week to screen for congenital cardiac lesions. 
Some cardiac anomalies can be diagnosed with a fi rst trimester 11 to 
14 week, or 14 to 16 week scan.(22)
The management of pregnant women with CHD in NYHA class I or II 
should include limiting strenuous exercise, having adequate sleep and 
rest, maintaining a low-salt diet, avoiding anemia (keep hemoglobin > 
11g), having frequent obstetrical and cardiovascular prenatal 
examinations  and monitoring for arrhythmias. 
The option to continue or interrupt the pregnancy in high risk patients 
should be discussed with the patient. If the pregnancy is continued, 
frequent rest is often required during part of the pregnancy with close 
cardiac and obstetric monitoring and prophylaxis for thromboembolism. 
Treatment of congestive heart failure is more challenging in pregnant 
than in nonpregnant women. Conservative measures are very 
important; however, pharmacologic therapy may be required, and 
medical options are limited due to adverse effects on the fetus. Maternal 
postpartum care should include early ambulation, attention to neonatal 
concerns, counseling with regard to breast feeding and consideration of 
contraception as appropriate.
TABLE 1: Genes associated with CHD (only most common types)
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OUTCOME OF PREGNANCY IN CHD                           
The pregnancy risk in CHD is dependent on: 1) the underlying cardiac 
defect, whether unoperated, palliated or repaired, 2) the use of chronic 
medication, 3) the presence of cyanosis, pulmonary hypertension or 
intracardiac shunts, 4) function of the subpulmonary ventricle, and 
5) the functional class. Due to the previously described hemodynamic 
changes during pregnancy, the outcome of pregnancy is affected by the 
presence of CHD and has recently been summarized in a large review 
by Drenthen et al.(12) including 2 491 pregnancies in women with 
different types of CHD. Cardiovascular events, rarely seen in the healthy 
general population, were documented in 11% of completed 
pregnancies.(12) Obstetric complications were not more prevalent than 
in the normal population apart from hypertensive and thromboembolic 
disorders. Pregnancy outcome was affected with a high offspring 
mortality rate (4% versus <1% in the general population) and a 
spontaneous miscarriage rate of 15%. Mortality and cardiovascular 
events were highest in mothers with Eisenmenger syndrome. Of note, 
endocarditis was most often observed in atrial septal defect; an 
explanation is lacking.
Arrhythmias occurred in >10 % of pregnant women with atrioventricular 
(AV) septal defect, transposition of the great arteries (TGA) and after 
Fontan palliation.(12) Supraventricular arrhythmias are most common in 
patients with TGA, Fontan, and AV septal defects. Heart failure is 
especially common in TGA, cyanotic heart disease, pulmonary atresia 
with VSD, and Eisenmenger syndrome (occurring in 21%). Hypertensive 
disorders are more common in aortic stenosis, pulmonary stenosis, 
aortic coarctation and TGA. Spontaneous preterm delivery is more 
common in more complex CHD including Ebstein, TGA, pulmonary 
valve atresia with VSD, Fontan, cyanotic CHD, and Eisenmenger, with 
preterm delivery rates between 22% and 65%.(12) Miscarriages are 
much more frequent than elective abortions in most CHD patients. 
However, after Fontan repair and in patients with pulmonary atresia 
with ventricular septal defects, the number of elective abortions is 
considerably higher than in other CHD patients (12% versus 5%).(12)
Maternal prognosis during pregnancy is strongly related to functional 
class. Siu and colleagues reported New York Heart Association (NYHA) 
functional class > 2 to be the strongest predictor of cardiovascular 
complication during pregnancy.(23) Additional factors that contribute to 
the risk of a cardiovascular complications during pregnancy include: a 
prior history of heart failure, transient ischemic attack, stroke or 
arrhythmia, the presence of cyanosis, left heart obstruction with either 
mitral stenosis with a mitral valve area < 2 cm2, or aortic stenosis with 
a peak left ventricular outfl ow tract gradient > 30 mmHg and aortic 
valve area < 1.5 cm2 by echocardiographic Doppler examination. 
Another study reported an increased cardiac and neonatal complication 
rate in women with CHD and impaired subpulmonary ventricular 
systolic function, severe pulmonary regurgitation, or a smoking 
history.(24)
Pregnancy risk classifi cation of various lesions in CHD is shown in 
Table II. The risk factors that predict outcome include: 1) poor 
functional class, 2) systemic ventricular ejection fraction < 40%, 
3) preconception history of arrhythmia, stroke transient ischemic attack, 
and pulmonary edema, or 4) left heart obstruction. The expected 
cardiac event rate ranges from 5, 27-75% with 0,1 or >1 risk factors.(3)
In contrast to fi xed obstructive cardiac lesions or those associated with 
pulmonary hypertension, shunts or regurgitant lesions are generally 
relatively well tolerated because of the pregnancy-related decrease in 
systemic vascular resistance.(25-27) Mitral valve prolapse is no 
contraindication for pregnancy.(27)
Medium or high-risk pregnancy includes women with 1) prosthetic 
valves; 2) obstructive lesions, including uncorrected coarctation of the 
aorta; 3) Marfan syndrome or other aortic disorders; 4) cyanotic CHD; 
5) pulmonary hypertension; 6) systemic ventricular dysfunction (ejection 
fraction <40%), or 7) signifi cant uncorrected CHD (see Table II).
TABLE 2: Pregnancy risk classiﬁ cation of various lesions of CHD
PHT = pulmonary hypertension; NYHA = New York Heart Association; EF = ejection fraction; 
TGA = transposition of the great arteries; CCTGA = congenitally corrected transposition of the great 
arteries; fi b = fi brillation





 Type of Risk Type of Lesion Main caveats  
Unrepaired/residual atrial or 
ventricular septal defect, no PHT
Unrepaired/residual patent ductus 
arteriosus, no PHT
Unrepaired regurgitant valvular 
heart disease, NYHA I/II 
Repaired Tetralogy of Fallot
Repaired left or right ventricular 
outfl ow tract stenosis/coarctation 
Unrepaired regurgitant, valvular 
heart disease, NYHA III/IV 
Unrepaired/residual mitral stenosis 
Aortic and/or mitral valve disease 
with severe left ventricular 
dysfunction, EF <40 %
Unrepaired/residual left or right 
ventricular outfl ow tract stenosis/
coarctation
Cyanotic lesions without PHT





Marfan syndrome, aortic root 
>4cm






Pre-eclampsia, heart failure, 
arrhythmias
Heart failure, arrhythmias




Systemic right ventricular failure, 
arrhythmias




11-50% risk of maternal death, 
arrythmias, heart failure
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CARDIAC CONTRAINDICATIONS TO PREGNANCY  
There are certain cardiac conditions in which pregnancy should be 
avoided, and if pregnancy occurs, termination should be considered. 
These include severe pulmonary hypertension (pulmonary artery 
pressure ≥ 3/4 systemic pressure) related to Eisenmenger syndrome or 
another cause; cardiomyopathy with class III or IV congestive heart 
failure or left ventricular dysfunction (ejection fraction <40%) and any 
form of severe obstructive cardiac lesion such as aortic stenosis, mitral 
stenosis, pulmonary stenosis, or coarctation; they may result in important 
morbidity and sometimes mortality during pregnancy. Intervention 
before pregnancy is the preferred management option if possible. 
Women with Marfan syndrome and an aortic root ≥40 mm should be 
strongly counseled to avoid pregnancy, because of the unpredictable 
risk of aortic dissection and rupture during pregnancy or postpartum.(18) 
Severe cyanosis is a relative contraindication to pregnancy, primarily 
because of adverse fetal outcome. 
MANAGEMENT OF PREGNANCY IN SELECT              
PATIENT GROUPS
Outcome of Pregnancy in Marfan Syndrome and other 
Aortopathies
In Marfan syndrome, an autosomal dominant inherited connective tissue 
disorder, pregnancy increases the risk of aortic dissection. On top of 
underlying inherited changes of the aortic media, the aorta is further 
affected by superimposed hormonal and hemodynamic changes during 
pregnancy. Relaxin, an insulin-like growth factor, is secreted during 
pregnancy.(28) This results in an unpredictable maternal risk of aortic 
dissection and rupture. Patients with Marfan syndrome who have an 
aortic dimension over 40mm should be counseled against pregnancy 
without aortic surgery due to the unpredictable risk of a cardiovascular 
event. According to the Canadian guidelines,(29) pregnancy is relatively safe 
in women with Marfan syndrome with an aortic root diameter less than 
45mm, and no signifi cant aortic and mitral regurgitation. However, there 
is a 1% risk of aortic dissection, endocarditis or congestive heart failure 
during pregnancy.(30) Cardiovascular complications were reported in 61 
women with Marfan syndrome; only one type B aortic dissection occurred 
in a patient with previous type A dissection.(31) No aortic dissection 
occurred in women with an aortic root diameter of less than 46mm.(31)
If pregnancy is being considered in a patient with Marfan syndrome, 
careful prepregnancy cardiovascular evaluation and counseling is 
recommended. Genetic counseling is also vital prior to pregnancy and 
should include a discussion about the risk of inheritance of Marfan 
syndrome (which is 50% per pregnancy), the variability of the disorder 
and the possibility of prenatal diagnosis. Once pregnant, patients with 
the Marfan syndrome should be followed closely with regular aortic 
imaging by echocardiography. Treatment with a beta-blocker during 
pregnancy is recommended. Fetal heart ultrasonography should be 
performed to assess the aorta and cardiac status of the fetus. Rare cases 
of severe Marfan syndrome may be diagnosed in the fetus. Near term, a 
facilitated delivery should be planned to avoid excessive strain on the 
aorta. If the aorta is over 40mm, or has enlarged during pregnancy, 
caesarean delivery should be considered. The postpartum period 
requires special monitoring. The risk of aortic dissection persists during 
this time and there is also an increased risk of postpartum hemorrhage.
Patients with bicuspid aortic valves and coarctation of the aorta 
associated with aortopathy as well as other aortopathies have a 
predisposition for aortic dissection and aneurysm formation, and this risk 
may be increased during pregnancy. Prepregnancy aortic assessment is 
imperative in these patients. Once pregnancy occurs beta-blockers may 
decrease the rate of dilatation of the aortic root and may be considered 
in all pregnant patients with aortopathy, although there are no data that 
demonstrate that beta-blocker therapy is benefi cial in this population. 
Regular aortic follow-up using echocardiography is recommended during 
pregnancy and shortly after birth in patients with aortopathy.
Outcome of Pregnancy in Left Ventricular Outfl ow Tract 
Obstruction
The two most common causes of left ventricular outfl ow tract 
obstruction include aortic stenosis and coarctation of the aorta. A 
fi xed outfl ow tract resistance may not accommodate the increased 
cardiac output in pregnancy and increases the risk of heart failure. Mild 
left ventricular outfl ow tract obstruction is usually tolerated well.
There are not many data on outcome of severe aortic stenosis in 
pregnancy. An initial review published in 1993 showed a maternal 
mortality of 11% among 65 women with aortic stenosis.(32) In a more 
recent study involving 35 women having 58 pregnancies, the outcome 
was more optimistic.(33) Hypertension related disorders occurred in 
11%, cardiac failure in 4%, and atrial arrhythmias in 6%.(33) Overall, an 
increase in obstetric and perinatal complications occurred. However, 
pregnancy is tolerated well in most women with congenital aortic 
stenosis. The outcome and management for supravalvular and 
subvalvular aortic stenosis does not differ signifi cantly from valvular 
aortic stenosis. The effect of pregnancy on a patient with valve disease 
depends on the specifi c valve lesion, ventricular function, pulmonary 
artery pressure, and on the New York Heart Association (NYHA) 
functional class. A careful cardiovascular evaluation should be performed 
prior to pregnancy in patients with valvular heart disease with a careful 
follow-up during pregnancy. 
Interventional procedures are effective alternatives to surgery in several 
cardiac disorders that occur during pregnancy. Preliminary reports are 
optimistic; however, no large series have reported on the safety of 
cardiac interventions during pregnancy. Percutaneous balloon aortic 
valvuloplasty has been reported as a safe and effective palliative 
procedure during pregnancy.(34-37) These procedures should be 
considered alternatives to surgery in patients with severe symptomatic 
native-valve stenosis identifi ed during pregnancy.
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Cardiac surgery should be reserved for patients refractory to medical 
management in whom further delay would prove detrimental to maternal 
and fetal health.(38) Cardiopulmonary bypass can adversely affect both 
the mother and fetus. High-fl ow, high-pressure, normothermic perfusion 
appears safest from a fetal standpoint. Fetal heart rate monitoring is 
recommended during cardiopulmonary bypass. When cardiac surgery is 
necessary during pregnancy, the optimal time is between the 24th and 
28th week of pregnancy and the duration of cardiopulmonary bypass 
should be kept as short as possible. Fetal death around the time of 
cardiac surgery is reported to be approximately 15%.
Coarctation of the thoracic aorta occurs in approximately 9% of 
pregnant women with CHD. The outcome of pregnancy in 50 women 
with coarctation was reported by Beauchesne et al.(39) 30 patients had 
coarctation repair before pregnancy, 10 had repair after pregnancy, 
4 had repair before and after pregnancy, and 6 had no history of repair. 
The 50 women had 118 pregnancies resulting in 106 births. 4% of the 
offspring had CHD. 38% had a gradient of ≥20 mmHg across the 
coarctation site during pregnancy. 30% had hypertension during 
pregnancy, 11 of whom (83%) had hemodynamically signifi cant 
coarctation during that time. A patient with Turner syndrome died of a 
Stanford type A dissection at 36 weeks of pregnancy. This review 
suggests that hemodynamically important coarctation should be 
repaired prior to pregnancy, and all patients with coarctation should 
undergo careful prepregnancy evaluation, including an assessment of 
the region of coarctation repair and the ascending aorta. Another study 
described the outcome of pregnancy in 54 women after coarctation 
repair that had 126 pregnancies resulting in 98 successful births. Overall, 
there was an excess of miscarriages and hypertensive disorders of 
pregnancy.(40) Coarctation is the only CHD known to be an independent 
predictor of pre-eclampsia.
Outcome of Pregnancy in Tetralogy of Fallot
Tetralogy of Fallot (TOF) represents 5-6% of CHD and includes anterior 
and superior infundibular septal displacement with ventricular septal 
defect, aortic override, infundibular obstruction, and right ventricular 
hypertrophy. Pregnancy is not advised in patients with unrepaired 
tetralogy of Fallot. After repair of tetralogy of Fallot, prognosis for a 
successful pregnancy is good unless there are important hemodynamic 
residua or functional capacity is reduced. The most common problems 
after TOF repair include pulmonary regurgitation or persistent outfl ow 
obstruction, tricuspid regurgitation, and right ventricular dysfunction.(3) 
Pregnancy is usually well tolerated even in the setting of severe 
pulmonary regurgitation, as long as the right ventricular function is no 
more than mildly depressed and sinus rhythm is maintained.(41) The risk 
of fetal loss is increased, and 6% of the offspring has congenital 
anomalies,(41) especially in the setting of a 22q11.2 microdeletion. 
Screening from 22q11.2 microdeletion should be considered in patients 
with conotruncal abnormalities prior to pregnancy in order to provide 
appropriate genetic counseling.(42) In the absence of 22q11 deletion, the 
risk of a fetus having CHD is approximately 4-6%. Fetal echocardiography 
should be offered to the mother in the second trimester. 
A comprehensive informed cardiovascular evaluation is recommended 
prior to each pregnancy.
Outcome of Pregnancy in Eisenmenger Syndrome or other 
causes of severe pulmonary hypertension and cyanosis
Severe pulmonary vascular disease has long been known to carry the 
highest risk, with maternal mortality of 12-50%(43-45) regardless of the 
cause. The fall in peripheral vascular resistance during pregnancy 
increases the right-to-left shunt and exaggerates cyanosis. Hypovolemia, 
thromboembolic events, and pre-eclampsia are particularly hazardous. 
Both vaginal and caesarean deliveries are associated with a high 
maternal death rate. In primary pulmonary hypertension (mortality 
30%) and Eisenmenger syndrome (36%), maternal mortality was 
comparable and better than in secondary vascular pulmonary 
hypertension (56%) in a study involving 125 patients.(46) In a more 
recent study, 3 stable patients on prostacyclin therapy and low-
molecular-weight heparin were able to successfully complete 
pregnancy.(47)
Pregnant cyanotic women have a high risk of fetal loss. Also, cyanosis is 
a recognized handicap to fetal growth, resulting in low birth weight 
infants.
Cyanosis is rare in women with CHD but associated with an increased 
pregnancy risk as shown in a prospective multicenter study.(23) Cyanotic 
women have an increased risk for neonatal and maternal cardiac 
complications. Due to known hemostatic defects, the odds ratio for 
postpartum hemorrhage was 27 (4-177) in cyanotic women (oxygen 
saturation <90%).(23)
PREGNANCY IN SURVIVORS OF CHD SURGERY        
Pregnant survivors of CHD surgery are increasingly encountered by 
obstetricians and often manifest unique problems during pregnancy. 
Patients with simple corrected lesions such as atrial septal defects may 
be at risk of arrhythmias during pregnancy and prepregnancy assessment 
is warrented. Patients with more complex repaired CHD may offer 
special problems due to residual lesions, prosthetic heart valves, an 
increased incidence of arrhythmias, a limited ability to increase cardiac 
output and an increased risk of pre-eclampsia or pregnancy related 
hypertension. The seemingly good health of a woman after CHD 
repair can deteriorate with pregnancy; thus, careful evaluation and 
consideration of possible complications should be performed prior to 
pregnancy. These patients are also at risk of increased obstetric 
(premature rupture of membranes, premature labor, postpartum 
hemorrhage, etc.) and neonatal complications (small for gestational age 
children, premature delivery). Multidisciplinary care is mandatory in 
these patients.
In women with prior atrial repair of complete TGA (Senning or Mustard 
repair), there is a high incidence of maternal cardiovascular complications 
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obstetric complications (premature labor and rupture of membranes), 
a high fetal and neonatal mortality rate (11.8%) and a high incidence of 
pre-eclampsia and pregnancy-induced hypertension.(48,49) 
Women following Fontan palliation have a higher infertility rate than 
other patients with CHD and they experience an increased risk of 
arrhythmias and miscarriage with pregnancy.(50)
PREGNANCY IN PATIENTS WITH PROSTHETIC        
HEART VALVES
The best type of heart valve prosthesis to use in women of childbearing 
age who have critical valvular heart disease is controversial.(27) Some 
data have suggested that premature valve deterioration occurs in 
bioprosthetic valves during pregnancy,(51) but this has not been 
documented conclusively or demonstrated experimentally. It has 
been suggested that reoperation (required for most patients with 
bioprosthetic valves) carries a higher risk of morbidity and mortality 
than the risk of anticoagulation during pregnancy. However, more 
recent surgical data would suggest that the risk of reoperation may not 
be substantially higher than the risk of the initial operation, depending 
on patient characteristics and surgical experience. The Ross procedure 
in young women requiring aortic valve replacement prior to pregnancy 
is an option;(52,53) however, institutions must have enough expertise in 
this diffi cult operation.
Pregnant women with a mechanical heart valve have an increased risk 
for developing prosthetic valve thrombosis or other life-threatening 
complications during pregnancy. The complication rate depends on the 
anticoagulation regimen used during pregnancy. The best management 
for a pregnant woman who requires anticoagulation is controversial 
(see section on Anticoagulation in Pregnancy).
CARDIOVASCULAR DRUGS IN PREGNANCY               
Drugs should be avoided whenever possible. Most cardiovascular drugs 
cross the placenta and are secreted in breast milk. The risk-to-benefi t 
ratio must be considered when administering any medications during 
pregnancy.(27) The following cardiovascular drugs are considered to be 
relatively safe during pregnancy (see comments below); these include 
digoxin, diuretics, select beta-blockers, calcium channel blockers, low 
dose aspirin, and intravenous low dose adenosine.(27) Not absolutely 
contraindicated are also other medications including amiodarone, 
fl ecainide, lidocaine, procainamide, propafenone and sotalol, which 
should be used with caution and can have considerable side effects.(27)
Medications that cause concern when administered during pregnancy 
include warfarin (skeletal defects, abnormalities of central nervous 
system), amiodarone (hypothyroidism, potential brain damage, 
intrauterine growth retardation, bradycardia and QT prolongation in 
the newborn), phenytoin (heart defects, orofacial abnormalities) and 
spironolactone (anomalies external genitalia). The use of angiotensin 
converting enzyme (ACE) inhibitors and angiotensin II receptor 
blockers is contraindicated during pregnancy. Maternal-fetal transfer of 
captopril has been documented and, in animals, exposure to ACE 
inhibitors during pregnancy has produced prolonged fetal hypotension 
and death. In addition, use of ACE inhibitors during pregnancy increases 
the risk of early delivery, low birth weight, Oligohydramnion, or neonatal 
anuria and renal failure (or some combination of these) and an increased 
risk of cardiovascular and central nervous system malformations.(54) 
However, these agents can be safely used during lactation.
Select beta-blockers (acebutolol, metoprolol, propranolol, labetalol) are 
thought to be relatively safe and may be used in the treatment of 
arrhythmias, hypertrophic cardiomyopathy, and hyperthyroidism during 
pregnancy if clinically indicated.(27) However, all available beta-blockers 
cross the placenta and are present in human breast milk.(55) These 
agents can reach signifi cant levels in the fetus or newborn. Therefore, if 
used during pregnancy, it is appropriate to monitor fetal and newborn 
heart rate as well as blood glucose and respiratory status after delivery. 
In pregnancies complicated by hypertension, adverse fetal effects have 
been associated with the use of atenolol, especially when atenolol was 
used in the fi rst trimester of pregnancy: then it was associated with low 
birth weight independent of pre-eclampsia.(56) There was a trend for 
early delivery and low birth weight, especially when atenolol was 
administered early in pregnancy. Additionally, some consider atenolol 
unsafe during breastfeeding as it may concentrate in breast milk, 
resulting in pharmacologically signifi cant dose to the breastfed infant 
with an increased risk for cyanosis, hypotension and bradycardia 
described in one case.(55) Safer alternatives such as acebutolol, 
propranolol or metoprolol should be used.
MANAGEMENT OF ARRHYTHMIAS DURING               
PREGNANCY
Cardiac arrhythmias during pregnancy should be evaluated the same as 
in a non-pregnant patient and the underlying disease or precipitating 
factors treated if possible.
Direct current cardioversion may be used and is the treatment of 
choice for arrhythmias causing hemodynamic compromise during 
pregnancy. For less urgent situations, pharmacologic management of 
arrhythmias may be required. Intravenous adenosine is the treatment of 
choice for supraventricular arrhythmias. 
ANTICOAGULATION DURING PREGNANCY              
The risk of thromboembolism is increased 6x during pregnancy and 
11x in the puerperium. Warfarin crosses the placenta and carries major 
risks for the fetus.(57,58) When warfarin is given throughout pregnancy in 
a patient with mechanical valve prosthesis, the risk of embryopathy is 
6.4%, the risk of spontaneous abortion 25% and thromboembolic 
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complications in 3.9%. Warfarin may be the safest form of anticoagulation 
for the mother. 
Unfractionated heparin does not cross the placenta and is thus safer for 
the fetus but it does not provide adequate anticoagulation coverage for 
the mother. Low molecular weight heparins are an alternative, but data 
supporting safe use in pregnancy for women with mechanical valve 
prostheses are lacking.(57-59) There are limited data on the effi cacy of low 
molecular weight heparin use during pregnancy in patients with 
mechanical valve prosthesis.
Labor and delivery is a particularly high-risk time for patients who 
require anticoagulation during pregnancy. Patients who are fully 
anticoagulated with warfarin are admitted around 36 weeks gestation 
and placed on full intravenous heparinization, allowing at least 4-5 days 
for warfarin to “wash-out” from the fetus. Delivery is planned and 
heparin is held 4-6 hours before the delivery. Caesarean delivery should 
be performed if unplanned labor occurs during warfarin anticoagulation 
because of the risk of fetal intracranial hemorrhage with vaginal delivery. 
Heparin should be resumed four to six hours after caesarean or vaginal 
delivery in the absence of bleeding. 
The European Society of Cardiology suggests continuation of warfarin 
anticoagulation during pregnancy and the American College of Chest 
Physicians recommend avoiding warfarin and using aggressive dose 
adjusted LMWH or unfractionated heparin during pregnancy.(60) 
Addition of low-dose aspirin for the high-risk patient was also suggested. 
Thus, there is no consensus on the best anticoagulation regimen during 
pregnancy for patients with mechanical valve prostheses. An informed 
discussion with the patient and her partner, and meticulous monitoring 
of the chosen anticoagulation regimen is mandatory. 
ENDOCARDITIS PROPHYLAXIS                                     
The American Heart Association does not recommend endocarditis 
prophylaxis for patients having caesarean or vaginal delivery.(61)
Our recommendations are more conservative. We recommend the 
intravenous administration of antibiotics for endocarditis prophylaxis 
using the gastrointestinal or genitourinary regimen in high-risk cardiac 
patients because of the risk of undiagnosed infections and the signifi cant 
patient morbidity and mortality should infective endocarditis occur. 
Antibiotic therapy should be administered 30 to 60 minutes before 
delivery is expected and repeated 8 hours later.
CONCLUSIONS                                                                    
As more women with CHD are reaching child-bearing age, and are 
considering pregnancy or becoming pregnant, detailed knowledge 
about possible complications and problems is mandatory. Pregnancy in 
CHD is feasible in most patients with good maternal and fetal outcome. 
High risk pregnancy patients with CHD have to be counseled by a 
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